Keywords: Takeda, NDA refiling, Diabetes, Alogliptin, Actos, USA

Takeda refiles NDAs with US FDA for diabetes drug alogliptin and combo with pioglitazone

Article | 27 July 2011

Print This

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it has resubmitted two New Drug Applications to the US Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in